ECHA -European Chemicals Agency (2016) . Guidance on information requirements and chemical safety assessment. Section R.7.4 of Chapter R.7a, last update December 2016. https://echa.europa.eu/documents/10162/13632/information_ requirements_r7a_en.pdf Gissi, A., Louekari, K., Hoffstadt, L. et al. (2017) . Alternative acute oral toxicity assessment under REACH based on subacute toxicity values. ALTEX 34, 353-361. doi:10.14573/ altex.1609121 Schrage, A., Hempel, K., Schulz, M. et al. (2011) . Refinement and reduction of acute oral toxicity testing: A critical review of the use of cytotoxicity data. Altern Lab Anim 39, like for any other 3R approach, acceptance in the European Union will not preclude full animal testing from being requested in other regions of the world.
In conclusion, while we agree that 3Rs methods are needed for regulatory toxicity testing, it does not serve the cause to publish studies that give the impression to serve to replace, reduce and refine animal testing, but that do not stand up to scrutiny. Instead, scientific evidence and practicability should govern 3Rs activities.
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First, we would like to point out that the purpose of our article (Gissi et al., 2017) is to clarify how a regulatory requirement can be adapted. In the REACH Regulation, there are many situations where the legal text formally mentions that an existing long-term test makes a short-term test unnecessary (e.g., subchronic studies can replace sub-acute studies, long-term aquatic toxicity can also cover short-term requirements), but nothing is mentioned for acute toxicity. With the analysis we presented, we have formalized how this could also be the case for acute toxicity. However, since the update of REACH legal text is a long process, the way to make such adaptations available to registrants before the 2018 REACH deadline was the update of ECHA's REACH Guidance text (ECHA, 2016) based on the results described in this paper.
1. The estimates of the number of cases for which an acute toxicity study may not be available for the incoming REACH registrations are given in our article and are based on statistics derived from all registration data hosted by ECHA. We agree that the cases for which an acute toxicity study is missing are not very common. However, because of the high number of new registrations in 2018, even a relatively small proportion of those (~10%, as explained in our article) would matter. Hence, to omit about 550 unnecessary animal tests with no scientific and regulatory value is worth exploring and communicating to the registrants. Furthermore, we ran a new analysis and found that about 24% of the substances that have a reliable and relevant sub-acute study provided, do not have an equivalently reliable and relevant acute oral toxicity study. For those substances, registrants have used weight of evidence (WoE) or other adaptations to cover the information requirement. With the update of ECHA's Guidance based on the results described in the article, registrants have one more possibility to use this adaptation. , 2016) and in our article; this implies that consistent evidence of low toxicity from reliable data sources can be used by the REACH registrants to propose an adaptation of this information requirement. In dossier evaluation, ECHA will assess these adaptions and find whether the scientific evidence gives a sufficient level of confidence on the proposed prediction of the acute oral toxicity. is performed. The wording of the Guidance refers to "existing data (… acute toxicity studies)", which is not the case we want the registrants to consider. It is obvious that for substances that already have both acute and subacute studies and for those with an acute oral study only, the approach that we suggest would not be applicable. We agree that the conventional order of testing is to start with an acute toxicity test and use the LD 50 value/ estimate to select the appropriate dose levels of the sub-acute study. The testing sequence that we propose mainly concerns substances for which both acute and sub-acute toxicity studies are missing, and both are required (i.e., REACH Annex VIII and above). In that situation, a registrant can perform the subacute study first, and if low toxicity (NOAEL above 1000 mg/ kg) is seen, the oral acute toxicity test becomes unnecessary, because a reliable prediction can be based on the results of the sub-acute toxicity study. Furthermore, we would like to point out that this testing sequence is clearly described in the revised Guidance (ECHA, 2016), Appendix R.7. In case the acute oral toxicity study is not performed, the dose selection for the sub-acute toxicity study could be based on existing information, such as data on analogue substances, predictions based on structure or on dose-range finding studies. Therefore, our article does not contradict the Guidance. Since new approaches are needed to maximize the use of already available in vivo study results, we wanted to explore this possibility and found that it can be scientifically supported.
